Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 13, 2023 (filed on Mar 15, 2023)Insider Name:Bleichroeder LPOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,498Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Sussman NormanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,557Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Sussman NormanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:45,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Papp Timothy M.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,377Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Papp Timothy M.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Joice Judy ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,456Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Joice Judy ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Brown James EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,665Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Brown James EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Aug 19, 2022 (filed on Aug 22, 2022)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:9,412Price:$0.85
Filings by filing date
-
Mar 13, 2023 (filed on Mar 15, 2023)Insider Name:Bleichroeder LPOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,498Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Sussman NormanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,557Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Sussman NormanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:45,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Papp Timothy M.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,377Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Papp Timothy M.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Joice Judy ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,456Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Joice Judy ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Brown James EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,665Price:--
-
Feb 21, 2023 (filed on Feb 23, 2023)Insider Name:Brown James EOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Aug 19, 2022 (filed on Aug 22, 2022)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:9,412Price:$0.85
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10260 Bubb Rd CUPERTINO CA 95014 |
Tel: | 1-646-3782928 |
Website: | https://www.durect.com |
IR: | See website |
Key People | ||
James E. Brown President, Chief Executive Officer, Director | Timothy M. Papp Chief Financial Officer, Company Secretary | Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance | Norman L. Sussman Chief Medical Officer |
Business Overview |
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company's other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology. |
Financial Overview |
For the three months ended 31 March 2023, DURECT Corp revenues increased 7% to $2.1M. Net loss increased 11% to $12M. Revenues reflect Europe segment increase of 28% to $431K, United States segment increase of 6% to $1.3M. Higher net loss reflects Other Research and development increase of 5% to $8.3M (expense), Selling and general increase of 12% to $3.8M (expense). |
Employees: | 75 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $118.02M as of Mar 31, 2023 |
Annual revenue (TTM): | $19.42M as of Mar 31, 2023 |
EBITDA (TTM): | -$35.58M as of Mar 31, 2023 |
Net annual income (TTM): | -$36.48M as of Mar 31, 2023 |
Free cash flow (TTM): | -$30.06M as of Mar 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,489,843 as of May 3, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |